Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

• By Mandy Jackson

MR image of Human brain

Related Content

New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests

Apr 15 2018

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

May 15 2018

Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study

Jan 23 2018

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Dec 02 2017

Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success

Nov 17 2016

Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Nov 13 2017

Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

Apr 28 2018

Teva Pushes CGRP Timeline Back To End Of 2018

May 03 2018

Repatha OK'd; Payers Eye PCSK9 Rebate/Discount War

Aug 28 2015

Related Companies

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Celltrion, Inc.

Eli Lilly and Company

Alder Biopharmaceuticals, Inc.

Biohaven Pharmaceutical Holding Company Ltd.

Allergan plc

Additional Topics

Approvals Launches Pricing Strategies Market Access Commercial Neurology BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window